logo
Plus   Neg
Share
Email

AstraZeneca, Daiichi Sankyo: Phase II DESTINY-Breast01 Trial Met Primary Goal

British drug major AstraZeneca Plc (AZN.L,AZN) and Daiichi Sankyo Co. Ltd. (DSKYF.PK) on Wednesday announced that the pivotal Phase II DESTINY-Breast01 trial of trastuzumab deruxtecan (DS-8201) met primary endpoint.

DESTINY-Breast01 is a pivotal Phase II, open-label, global, multicentre, two-part trial of trastuzumab deruxtecan. The HER2-targeting antibody drug conjugate or ADC and potential new medicine was evaluated in patients with HER2-positive, unresectable and/or metastatic breast cancer previously treated with trastuzumab emtansine.

The companies expect the positive top-line results to support planned global regulatory submissions, including a Biologics License Application with the US Food and Drug Administration or FDA, anticipated in the second half of 2019.

Trastuzumab deruxtecan has been granted US FDA Breakthrough Therapy Designation and Fast Track Designation for HER2-positive patients in the advanced or refractory breast cancer setting.

José Baselga, Executive Vice President, R&D Oncology, said, "We are encouraged to see positive data from trastuzumab deruxtecan, with the DESTINY-Breast01 trial now reinforcing what earlier data have shown. …. we are eager to bring it as quickly as possible to patients with refractory HER2-positive breast cancer who continue to have high unmet medical need."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Fast-food chain Burger King has tested a new recipe for cow's diet to offer its customers reduced methane emission beef. It partnered with globally renowned scientists to develop and test a new diet for cows, which will help reduce cows' daily methane emissions. The second largest fast food hamburger chain in the world will begin offering the Reduced Methane Emissions Beef Whopper sandwich. The New York Times announced its plans to relocate its Hong Kong-based digital news operation to South Korea's Seoul, amid uncertainty following China's tough national security law for the semi-autonomous city. The news organization cited the possible impact of Beijing's new security law to the city's prospects as a hub for journalism in Asia. Search giant Google, Inc. announced Wednesday that it signed an agreement to invest $4.5 billion or 33,737 crore Indian rupees in India's Jio Platforms Ltd, taking a 7.73 percent stake in the company, pending regulatory review in India. This investment by Google values Jio Platforms at an equity value...
Follow RTT